SMART Trial two-year data continues to demonstrate superior valve performance for Evolut TAVR™ system in small annulus patients

Core Insights - The SMART Trial presents the two-year results of the largest international head-to-head randomized control trial comparing Evolut and SAPIEN TAVR devices, primarily enrolling women with small aortic annuli [1][3][4] - Evolut TAVR demonstrated superior valve performance and significantly less bioprosthetic valve dysfunction (BVD) compared to SAPIEN TAVR, which is critical for patients with small aortic annuli [2][4][6] Company Overview - Medtronic plc is a global leader in healthcare technology, headquartered in Galway, Ireland, with a mission to alleviate pain, restore health, and extend life [6] - The company employs over 95,000 people across 150 countries, focusing on innovative technologies that address challenging health problems [6][7] Industry Context - Aortic stenosis affects approximately 1.5 million people in the U.S., with a significant portion of the global market having small aortic annuli, necessitating tailored valve selection [5] - The SMART Trial's findings are expected to inform and personalize treatment decisions for patients with symptomatic severe aortic stenosis [2][4]